SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Vivimed Labs to acquire Finoso Pharma for Rs 15 crore

15 Feb 2013 Evaluate

Vivimed Labs has proposed to acquire Finoso Pharma for a total consideration of Rs 15 crore comprising cash, stock and deferred payment. Post acquisition, Finoso will become Vivimed’s research and development (R&D) unit to support innovators, generics and licensing efforts.

Finoso Pharma is a pharmaceutical development services company focused on formulations product development efforts for multiple markets and develops globally accepted dossiers.

Vivimed Labs Share Price

7.64 -0.15 (-1.93%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×